Exelixis | EXEL - Stock



Exelixis reported $23.48M in Stock for its fiscal quarter ending in June of 2025.


Stock Change Date
Acadia Pharmaceuticals USD 26.12M 3.18M Jun/2025
Agios Pharmaceuticals USD 30.85M 1.24M Jun/2025
Amgen USD 6.58B 146M Jun/2025
AstraZeneca USD 6.47B 583M Jun/2025
Bayer EUR 12.11B 576M Jun/2025
BioMarin Pharmaceutical USD 1.34B 65.32M Jun/2025
Bristol-Myers Squibb USD 2.74B 71M Jun/2025
Cytokinetics 0 0 Dec/2023
Eisai JPY 227.32B 11.41B Jun/2025
Eli Lilly USD 11.01B 1.7B Jun/2025
Exelixis USD 23.48M 1.37M Jun/2025
Genmab DKK 13M 1000K Jun/2025
Glaxosmithkline 6.07B 403M Jun/2025
Incyte USD 83.42M 19.45M Jun/2025
Ionis Pharmaceuticals USD 8.48M 3.02M Jun/2025
MacroGenics USD 9.28M 9.28M Jun/2025
Merck USD 6.6B 405M Jun/2025
Moderna USD 240M 112M Jun/2025
Neurocrine Biosciences USD 56.9M 2.2M Jun/2025
Novartis USD 6.31B 478M Jun/2025
Pfizer USD 11.67B 817M Jun/2025
Sanofi 9.62B 187M Jun/2025
Takeda JPY 1.24T 23.33B Jun/2025
Ultragenyx Pharmaceutical USD 46.5M 467K Jun/2025
Xencor USD 0 0 Jun/2020